Concepedia

Publication | Open Access

Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*

DOIFull Paper Access

26

Citations

28

References

2022

Year

Julien Carvelli, Ferhat Meziani, Jean Dellamonica, Pierre‐Yves Cordier, Jérôme Allardet-Servent, Megan Fraissé, Lionel Velly, Saber Davide Barbar, Samuel Lehingue, Christophe Guervilly,
Critical Care Medicine

Abstract

In this randomized trial in hospitalized patients with severe COVID-19 pneumonia, avdoralimab did not significantly improve clinical status at days 14 and 28 (funded by Innate Pharma, ClinicalTrials.gov number, NCT04371367).

References

YearCitations

Page 1